Equity Profile

PFE

Pfizer Inc.

Health CarePharmaceuticals$148.0B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Pfizer Inc. is a leading pharmaceutical company known for developing and producing medications and vaccines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is critical for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PFE Q2-2026 Earnings Preview

Context

Company Snapshot

Pfizer Inc. is a leading pharmaceutical company known for developing and producing medications and vaccines. With a market cap of $148 billion, it plays a crucial role in the healthcare sector, especially following its prominent role in COVID-19 vaccine development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+33.22%

Avg Stock Reaction

+0.46%

Last Quarter Recap

In Q1 2026, Pfizer reported an EPS of $0.75, exceeding expectations by 5.63%. The stock reacted positively, gaining 0.57% the following day.

Management Promises & Guidance

Continue focusing on innovative treatments.
Expand vaccine distribution efforts.
Enhance research and development capabilities.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given Pfizer's strong track record of beating EPS estimates.

Bull Case

If Pfizer continues its trend of exceeding EPS expectations, it could signal robust demand for its products and lead to a significant stock price increase.

Bear Case

Concerns about declining vaccine sales and potential regulatory challenges could weigh on the stock if earnings do not meet expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

How are vaccine sales trending compared to previous quarters?

Given the reliance on vaccine revenue, understanding sales trends will be crucial for assessing future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Pfizer's ability to sustain its growth trajectory, especially in non-vaccine segments.

Supporting Evidence

Pfizer has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a larger move than historical averages suggest, indicating potential for a surprise.

Recent insider trading activity shows confidence in the company's future prospects.

Key Risk

If vaccine sales decline more than expected, it could undermine the overall growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Pfizer's ability to maintain its earnings momentum amid changing market dynamics.

Bull Confirmed If

An EPS of $0.80 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.70 could raise concerns about declining sales and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±9.1%

Historical Avg

±2.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±9.1% while PFE has averaged ±2.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

16.8%

Calls (3.2M)P/C Ratio: 0.44Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Pfizer beats expectations, history suggests a potential stock increase of around 0.46%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting a potential drop around 0.46%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House only

Est. Notional

$103,004.00–$295,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Details on vaccine sales trends and future expectations.
3Any changes to guidance or strategic priorities.
4Insights into R&D pipeline developments.
5Management's outlook on market conditions and competition.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Pfizer Inc. is a leading pharmaceutical company known for developing and producing medications and vaccines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is critical for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PFE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+33.22%

Avg Stock Reaction

+0.46%

Last Quarter Recap

In Q1 2026, Pfizer reported an EPS of $0.75, exceeding expectations by 5.63%. The stock reacted positively, gaining 0.57% the following day.

Management Promises & Guidance

Continue focusing on innovative treatments.
Expand vaccine distribution efforts.
Enhance research and development capabilities.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given Pfizer's strong track record of beating EPS estimates.

Bull Case

If Pfizer continues its trend of exceeding EPS expectations, it could signal robust demand for its products and lead to a significant stock price increase.

Bear Case

Concerns about declining vaccine sales and potential regulatory challenges could weigh on the stock if earnings do not meet expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

How are vaccine sales trending compared to previous quarters?

Given the reliance on vaccine revenue, understanding sales trends will be crucial for assessing future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Pfizer's ability to sustain its growth trajectory, especially in non-vaccine segments.

Supporting Evidence

Pfizer has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a larger move than historical averages suggest, indicating potential for a surprise.

Recent insider trading activity shows confidence in the company's future prospects.

Key Risk

If vaccine sales decline more than expected, it could undermine the overall growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Pfizer's ability to maintain its earnings momentum amid changing market dynamics.

Bull Confirmed If

An EPS of $0.80 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.70 could raise concerns about declining sales and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±9.1%

Historical Avg

±2.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±9.1% while PFE has averaged ±2.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

16.8%

Calls (3.2M)P/C Ratio: 0.44Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Pfizer beats expectations, history suggests a potential stock increase of around 0.46%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting a potential drop around 0.46%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House only

Est. Notional

$103,004.00–$295,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Details on vaccine sales trends and future expectations.
3Any changes to guidance or strategic priorities.
4Insights into R&D pipeline developments.
5Management's outlook on market conditions and competition.